TICKERNERD
Menu
QUREQUREHealthcare · Biotechnology

QURE Stock Forecast: UniQure NV Price Predictions for 2026-2027

Last close, 6 Oct 2026
$23
+1.14% on the day

The 12 Wall Street analysts covering UniQure NV hold a median 12-month price target of $69 — +200.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 6 Oct 2026 — in the lower half.

Market cap
$1.6B
Ticker Nerd rank
47 / 100
Median analyst target
$69
Analysts covering
12
Revenue$5.8M+11.0% y/y
Operating income−$44.7M
Net income−$81.1M
Free cash flow−$29.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
−48.2%
YTD
−3.6%
1Y
−56.4%
From 52W high
−67.3%
From 52W low
+155.4%
$9
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QURE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores UniQure NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
89
Accruals
65
Momentum
61
Value
56
Revisions
51
Growth
50
Size
38
Issuance
16
Volatility
11

Quality (89): The business earns solid, repeatable profits on what it owns.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QURE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QURE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26QUREHigh $92Median $69Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $28Median $69High $92

The green dot is the last close — the median target sits +200.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
5 Oct 2026BarclaysDowngradeEqual-Weight$60 → $28
2 Oct 2026RBC CapitalMaintainsOutperform$65 → $48
30 Sept 2026Goldman SachsMaintainsNeutral$46 → $31
2 Sept 2026William BlairReinstatesOutperform—
30 July 2026BarclaysMaintainsOverweight—
30 July 2026BarclaysMaintainsOverweight$65 → $60
30 July 2026Wells FargoMaintainsOverweight$60 → $75
30 July 2026Wells FargoMaintainsOverweight—
30 July 2026Wolfe ResearchUpgradeOutperform—
30 July 2026Wolfe ResearchUpgradeOutperform$65
29 June 2026HC Wainwright & Co.MaintainsBuy$50 → $80
29 June 2026HC Wainwright & Co.MaintainsBuy—
25 June 2026MizuhoMaintainsOutperform$35 → $68
25 June 2026MizuhoMaintainsOutperform—
18 June 2026BarclaysUpgradeOverweight—
18 June 2026Goldman SachsMaintainsNeutral—
18 June 2026Leerink PartnersMaintainsOutperform—
18 June 2026RBC CapitalMaintainsOutperform—
6 May 2026HC Wainwright & Co.MaintainsBuy—
30 Apr 2026Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QURE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QURE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, UniQure NV returned −56.4% against +17.3% for the S&P 500, dividends included.

QURE vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26QURES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QURE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

UniQure NV (QURE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.6×

Cheaper than 91% of US stocks

Price / sales
84.7×

Cheaper than 4% of US stocks

Price / book
4.9×

Cheaper than 20% of US stocks

EV / EBITDA
−7.2×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
11.0%

Higher than 55% of US stocks

Earnings growth (YoY)
11.0%

Higher than 49% of US stocks

Gross margin
94.0%

Higher than 98% of US stocks

Operating margin
−872.2%

Higher than 6% of US stocks

Net margin
89.5%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−157.6%

Higher than 9% of US stocks

Return on assets
−15.7%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

UniQure NV (QURE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • UniQure NV has a market value of $1.6B and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter grew 11.0% year on year.

  • Net income over the same four quarters: −$252.2M, a −1350.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$161.5M.

  • Shares outstanding: 69.3M.

  • Trailing P/E: −6.6×; forward P/E: −7.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • UniQure NV employs 221 people — $84K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

QURE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QUREUniQure NV$1.6B
47
INVAInnoviva, Inc.$1.6B
87
SEPNSepterna, Inc.$1.6B
90
OCULOcular Therapeutix, Inc.$1.6B
32
STOKStoke Therapeutics, Inc.$1.5B
52
SNDXSyndax Pharmaceuticals, Inc.$1.5B
60
RAPPRapport Therapeutics, Inc.$1.5B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own UniQure NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QURE news & analysis

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop

Business Wire · 6 Oct 2026negative

Kirby McInerney LLP said it is investigating possible federal securities law violations or other unlawful business practices by uniQure and/or its senior management. The notice references a 37.3% share drop and the company’s September 29, 2026 release of 48-month data from ongoing Phase I/II AMT-130 studies.

Why it matters — QURE investors may follow the investigation and the cited AMT-130 data release as developments involving the company.

10 Stocks With Massive Short Squeeze Potential

Schaeffers Research · 1 Oct 2026neutral

Schaeffers Research published a list of 10 stocks with massive short squeeze potential, framed against a backdrop of rising bond yields, oil prices, and inflation rhetoric heading into Q4, with UniQure among the names examined as short sellers reposition.

Why it matters — A QURE watcher would care because the stock's inclusion on a short-squeeze watchlist signals notable short interest and the potential for outsized price moves based on market sentiment and positioning.

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

GlobeNewsWire · 30 Sept 2026negative

Kirby McInerney LLP announced it is investigating potential claims against uniQure N.V. over whether the company and/or senior management may have violated federal securities laws or engaged in other unlawful business practices. The firm is inviting investors who acquired uniQure securities to contact it about their rights.

Why it matters — A securities investigation against the company raises legal and regulatory risk that could affect QURE shareholders.

uniQure Plunges on Additional Data From Huntington's Disease Study

Zacks Investment Research · 30 Sept 2026negative

uniQure's Huntington's disease gene therapy showed sustained functional benefits at 36 months, but newly reported 48-month data were mixed, injecting uncertainty into the program. The company's stock fell on the additional data release.

Why it matters — The mixed longer-term data add uncertainty around the durability of uniQure's key Huntington's disease therapy, a central driver of the company's valuation.

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

Seeking Alpha · 30 Sept 2026positive

uniQure reported four-year AMT-130 data for Huntington's Disease on Sep. 29, showing a 44% slowing on cUHDRS (non-significant p=0.144) and over 60% slowing on TFC with nominal statistical significance. The company attributed the cUHDRS result to missing data and survivor bias in the external control arm.

Why it matters — A QURE watcher would care because the TFC endpoint, which is the primary endpoint of the FDA-aligned confirmatory Phase 3 trial, showed consistent and statistically significant slowing of disease progression across four years.

FAQ

Frequently asked questions about QURE stock

What is the QURE stock price forecast for 2026-2027?

The 12 Wall Street analysts covering UniQure NV have a median 12-month price target of $69, with estimates ranging from $28 to $92. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QURE stock a buy right now?

Of the 12 analysts covering UniQure NV, 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UniQure NV 47 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QURE?

As at 6 Oct 2026, UniQure NV ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (89 of 100).

Will QURE stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +200.3% from the last close, and Ticker Nerd's factor model ranks UniQure NV 47 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QURE stock forecast for 2030?

No analyst covering UniQure NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QURE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $92 over the next 12 months.

How has QURE stock performed over the past year?

UniQure NV returned -56.4% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does UniQure NV do?

uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases.

What is the latest news on QURE?

The most recent item we track (Business Wire, 6 Oct 2026): "UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop". Kirby McInerney LLP said it is investigating possible federal securities law violations or other unlawful business practices by uniQure and/or its senior management. The notice references a 37.3% share drop and the company’s September 29, 2026 release of 48-month data from ongoing Phase I/II AMT-130 studies.

Company

About UniQure NV.

uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.

CEO Mr. Matthew Craig Kapusta CPA · 221 employees · Netherlands · https://www.uniqure.com